Janet Woodcock, director of the Center for Drug Evaluation and Research (AP Images)
Government gears for unprecedented challenge of Eli Lilly antibody rollout as efficacy questions linger
After months of anticipation, the FDA has authorized the first antibody treatment for Covid-19. Now what?
The US government faces a challenge unlike virtually …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
